當(dāng)前位置:杭州昊鑫生物科技股份有限公司>>MCE>>抑制劑>> HY-10219Rapamycin抑制劑
HY-10219
MCE
代理商
杭州市
10 605元 10000支可售
10 550元 10000支可售
聯(lián)系方式:鄧女士查看聯(lián)系方式
更新時間:2023-05-22 15:22:23瀏覽次數(shù):507次
聯(lián)系我時,請告知來自 制藥網(wǎng)| CAS號 | 53123-88-9 | 產(chǎn)地 | 進(jìn)口 |
|---|---|---|---|
| 級別 | 其他 | 證書 | ISO系列證書 |
注:本產(chǎn)品僅用于科研,不可用于臨床
生物活性
Rapamycin (Sirolimus; AY 22989) is a potent and specific mTOR inhibitor with an IC50 of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1[1]. Rapamycin is an autophagy activator, an immunosuppressant
體外研究
(In Vitro)
Rapamycin(12.5-100 nM;24 小時)處理在所有測試的細(xì)胞系(A549、SPC-A-1、95D 和 NCI-H446 細(xì)胞)中以劑量依賴性方式對肺癌細(xì)胞增殖產(chǎn)生適度抑制作用,達(dá)到約 100 nM 時細(xì)胞增殖減少 30-40%,而 12.5 nM 時減少約 10%[3]。
將肺癌細(xì)胞系 95D 細(xì)胞單獨(dú)或聯(lián)合暴露于 Rapamycin(10 nM、20 nM)和 RP-56976(1 nM、10 nM)(Rapamycin 20 nM + RP-56976 10 nM)。單獨(dú)暴露于 Rapamycin 或 RP-56976 24 小時后,不會顯著改變 ERK1/2 的表達(dá)或磷酸化水平,而 Rapamycin 與 RP-56976 聯(lián)合處理的細(xì)胞表現(xiàn)出 ERK1/2 磷酸化水平的顯著降低[3]。
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Cell Viability Assay[3]
| Cell Line: | Lung cancer cell lines A549, SPC-A-1, 95D and NCI-H446 |
| Concentration: | 12.5 nM, 25 nM, 50 nM, 100 nM |
| Incubation Time: | 24 hours |
| Result: | Treatment exerted modest inhibitory effect on lung cancer cell proliferation in a dose-dependent manner in all cell lines. |
體內(nèi)研究
(In Vivo)
Rapamycin (2.0 mg/kg; 腹腔內(nèi)注射; 每隔一天;28 天) 單獨(dú)使用有中等的抑制作用。然而,與對照組、Rapamycin 組相比,metformin聯(lián)合 Rapamycin 對腫瘤生長的抑制作用明顯增強(qiáng)[4]。
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | 24 male nu/nu mice aged 4-5 week old (15-20 g)[4] |
| Dosage: | 2.0 mg/kg |
| Administration: | Intraperitoneal injection; every other day; 28 days |
| Result: | Had a moderate inhibitory effect in monotherapy group. The combination with Metformin exerted a significantly increased inhibition of tumor growth. |
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT03826628 | Dermatology Specialties Limited Partnership | July 28, 2019 | Phase 2|Phase 3 | |
| NCT05556681 | C. R. Bard | August 2, 2022 | ||
| NCT01223755 | Mario Negri Institute for Pharmacological Research |
分子量
914.17
性狀
Solid
Formula
C51H79NO13
CAS 號
53123-88-9
中文名稱
雷帕霉素;sirolimus
來源
bacterium Streptomyces hygroscopicus
運(yùn)輸條件
Room temperature in continental US; may vary elsewhere.
儲存方式
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 months |
請輸入賬號
請輸入密碼
請輸驗證碼
以上信息由企業(yè)自行提供,信息內(nèi)容的真實(shí)性、準(zhǔn)確性和合法性由相關(guān)企業(yè)負(fù)責(zé),制藥網(wǎng)對此不承擔(dān)任何保證責(zé)任。
溫馨提示:為規(guī)避購買風(fēng)險,建議您在購買產(chǎn)品前務(wù)必確認(rèn)供應(yīng)商資質(zhì)及產(chǎn)品質(zhì)量。